Effect of dopaminergic drug treatment on surgical findings in prolactinomas

Pituitary

Volumn 14, Issue 1, 2011, Pages 68-74

  Menucci, Maria ^a   Quiñones Hinojosa, Alfredo ^b   Burger, Peter ^a   Salvatori, Roberto ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cabergoline; Dopamine agonist; Pituitary adenoma; Prolactinoma; Tumor fibrosis

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; GROWTH HORMONE; PROLACTIN; QUINAGOLIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; CRANIOTOMY; DIABETES INSIPIDUS; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPITUITARISM; INAPPROPRIATE VASOPRESSIN SECRETION; LIQUORRHEA; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROLACTINOMA; REMISSION; RETROSPECTIVE STUDY; SINUSITIS; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME; VEIN THROMBOSIS;

ADENOMA; ADOLESCENT; ADULT; AGED; BROMOCRIPTINE; CHILD; DOPAMINE AGENTS; ERGOLINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79951956242     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-010-0261-4     Document Type: Article

References (34)

1. JA Schlechte 2003 Prolactinoma N Engl J Med 349 2035 2041 1:CAS:528:DC%2BD3sXptFKmu7w%3D 10.1056/NEJMcp025334 14627789 (Pubitemid 37448927)
2. A Ciccarelli AF Daly A Beckers 2005 The epidemiology of prolactinomas Pituitary 8 3 6 10.1007/s11102-005-5079-0 16411062 (Pubitemid 44680079)
3. A Colao A Di Sarno E Guerra M De Leo A Mentone G Lombardi 2006 Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women Nat Clin Pract Endocrinol Metab 2 200 210 1:CAS:528: DC%2BD28XksFSrtLk%3D 10.1038/ncpendmet0160 16932285
4. MP Gillam ME Molitch G Lombardi A Colao 2006 Advances in the treatment of prolactinomas Endocr Rev 27 485 534 10.1210/er.2005-9998 1:CAS:528: DC%2BD28XpvVelurY%3D 10.1210/er.2005-9998 16705142 (Pubitemid 44213229)
5. JS Bevan J Webster CW Burke MF Scanlon 1992 Dopamine agonists and pituitary tumor shrinkage Endocr Rev 13 220 240 1:CAS:528:DyaK38XltVeguro%3D 1352243
6. JB Tyrrell K Lambourn L Hannegan CB Applebury CB Wilson 1999 Transsphenoidal microsurgical therapy of prolactinomas: initial outcome and long-term results Neurosurgery 44 254 261 1:STN:280:DyaK1M7ivFKmug%3D%3D 10.1097/00006123-199902000-00006 9932878 (Pubitemid 29068168)
7. J Webster MD Piscitelli A Polli, et al. 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea N Engl J Med 331 904 909 1:STN:280:DyaK2czlvFGksg%3D%3D 10.1056/NEJM199410063311403 7915824 (Pubitemid 24299871)
8. J Verhelst R Abs D Maiter, et al. 1999 Cabergoline in the treatment of hyperprolactinemia J Clin Endocrinol Metab 84 2518 1:CAS:528:DyaK1MXks1ansr4%3D 10.1210/jc.84.7.2518 10404830
9. FF Casanueva ME Molitch JA Schlechte R Abs V Bonert MD Bronstein T Brue P Cappabianca A Colao R Fahlbusch H Fideleff M Hadani P Kelly D Kleinberg E Laws J Marek M Scanlon LG Sobrinho JAH Wass A Giustina 2006 Guidelines of the pituitary society for the diagnosis and management of prolactinomas Clin Endocrinol 65 265 273 10.1111/j.1365-2265.2006.02562.x (Pubitemid 44079693)
10. AM Landolt V Osterwalder 1984 Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58 1179 1183 1:STN:280:DyaL2c3ht12qtA%3D%3D 10.1210/jcem-58-6-1179 6725514 (Pubitemid 14084037)
11. MM Esiri JS Bevan CW Burke CB Adams 1986 Effect of bromocriptine treatment on the fibrous tissue content of prolactinsecreting and nonfunctioning macroadenomas of the pituitary gland J Clin Endocrinol Metab 63 383 388 1:STN:280:DyaL283ltFWrsg%3D%3D 10.1210/jcem-63-2-383 3722328 (Pubitemid 16035685)
12. T Takahashi A Kuwayama T Katoh N Kageyama 1986 Histological changes and operative findings of pituitary adenomas after bromocriptine treatment Nippon Naibunpi Gakkai Zasshi 62 1336 1351 1:STN:280:DyaL2s7jsVChtw%3D%3D 3817228
13. M Gen T Uozumi M Ohta A Ito H Kajwara S Mori 1984 Necrotic changes in prolactinomas after long-term administration of bromocriptine J Clin Endocrin Metab 59 463 1:STN:280:DyaL2c3msFSrsw%3D%3D 10.1210/jcem-59-3-463
14. M Scanarini 1990 Morphological changes in prolactinoma induced by bromocriptine treatment Minerva Endocrinol 15 1 13 15 1:STN:280: DyaK3M7gvFKksw%3D%3D 2274009
15. JL Hubbard BW Scheithauer CF Abnoud ER Laws 1987 Prolactin-secreting adenomas: the preoperative response to bromocriptine treatment and surgical outcome J Neurosurg 67 816 821 1:STN:280:DyaL1c%2FmtFGquw%3D%3D 10.3171/jns.1987.67.6.0816 3681421 (Pubitemid 18005525)
16. H Nishioka J Haraoka K Akada S Azuma 2002 Gender-related differences in prolactin secretion in pituitary prolactinomas Neuroradiology 44 5 407 410 1:STN:280:DC%2BD383nt1CnsA%3D%3D 10.1007/s00234-002-0774-2 12012125 (Pubitemid 36097191)
17. ME Molitch MO Thorner C Wilson 1997 Therapeutic controversy: management of prolactinomas J Clin Endocrinol Metab 82 996 1000 1:CAS:528: DyaK2sXitlOitbs%3D 10.1210/jc.82.4.996 9100563 (Pubitemid 27166632)
18. M Losa P Mortini R Barzaghi L Gioia M Giovanelli 2002 Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome J Clin Endocrinol Metab 87 3180 3186 1:CAS:528:DC%2BD38XlsVGjtL0%3D 10.1210/jc.87.7.3180 12107221 (Pubitemid 34816362)
19. ZQ Xu CB Su ZY Ren RZ Wang Y Yang WB Ma YN Li B Xing W Lian Z Yang 2008 Transsphenoidal microsurgical results of non-invasive prolactinomas Zhonghua Wai Ke Za Zhi 46 293 295 18683769
20. DK Hamilton M Lee Vance PT Boulos ER Laws 2005 Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists Pituitary 8 53 60 10.1007/s11102-005-5086-1 16411069 (Pubitemid 44680086)
21. JA Thompson DL Davies EH McLaren GM Teasdale 1994 Ten year follow-up of microprolactinoma treated by transsphenoidal surgery BMJ 309 409 410
22. DA Rees JS Davies MF Scanlon 2000 Microprolactinoma: medical or surgical treatment as first line approach? The case for medical therapy J Endocrinol Invest 23 122 124 1:CAS:528:DC%2BD3cXis1entrg%3D 10800767 (Pubitemid 30189274)
23. ME Molitch MO Thorner C Wilson 1997 The case for initial surgical removal of certain prolactinomas J Clin Endocrinol Metab 82 996 1000 1:CAS:528:DyaK2sXitlOitbs%3D 10.1210/jc.82.4.996 9100563 (Pubitemid 27166632)
24. M Giovanelli M Losa P Mortini S Acerno E Giugni 1996 Surgical results in microadenomas Acta Neurochir Suppl 65 11 12 1:STN:280:DyaK28zjs1aqtA%3D%3D 8738484
25. MH Weiss RR Wycoff R Yadley P Gott S Feldon 1983 Bromocriptine treatment of prolactin-secreting tumors: surgical implications Neurosurgery 12 640 642 1:STN:280:DyaL3s3ntFygsQ%3D%3D 10.1227/00006123-198306000-00008 6877546 (Pubitemid 13066923)
26. ME Sughrue EF Chang JB Tyrell S Kunwar CB Wilson LS Blevins Jr 2009 Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection Pituitary 12 158 164 1:CAS:528: DC%2BD1MXoslamur0%3D 10.1007/s11102-008-0135-1 18651225
27. M Ono N Miki T Kawamata R Makino K Amano T Seki O Kubo T Hori K Takano 2008 Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients J Clin Endocrinol Metab 93 4721 4727 10.1210/jc.2007-2758 1:CAS:528:DC%2BD1cXhsVyqtbrI 10.1210/jc.2007-2758 18812485
28. J Webster G Piscitelli A Polli CI Ferrari I Ismail MF Scanlon 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea N Engl J Med 331 904 909 1:STN:280: DyaK2czlvFGksg%3D%3D 10.1056/NEJM199410063311403 7915824 (Pubitemid 24299871)
29. A Colao A DiSarno S Sarnacchiaro, et al. 1997 Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment J Clin Endocrinol Metab 82 876 883 1:CAS:528:DyaK2sXhsl2iu7c%3D 10.1210/jc.82.3.876 9062500 (Pubitemid 27106605)
30. S Cannavo L Curto S Squadrito B Almoto A Vieni F Trimarchi 1999 Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenomas J Endocrinol Invest 22 354 359 1:CAS:528:DyaK1MXjvFOmurc%3D 10401709 (Pubitemid 29259557)
31. V Pascal-Vigneron G Weryha M Bosc J Leclere 1995 Hyperprolactinemic amenorrhea: treatment with cabergoline vs bromocriptine. Results of a national multicenter randomized double-blind study Presse Med 24 753 757 1:STN:280:DyaK2Mzgtlyltg%3D%3D 7784413
32. M Lafeber AM Stades GD Valk MJ Cramer F Teding van Berkhout PM Zelissen 2010 Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline Eur J Endocrinol 162 667 675 1:CAS:528: DC%2BC3cXlt1Kitr4%3D 10.1530/EJE-09-0989 20071478
33. S Bhattacharyya AH Schapira DP Mikhailidis J Davar 2009 Drug-induced fibrotic valvular heart disease Lancet 374 9689 577 8529 1:CAS:528: DC%2BD1MXpvFygurY%3D 10.1016/S0140-6736(09)60252-X 19683643
34. S Vallette K Serri O Serri 2010 Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? Expert Rev Cardiovasc Ther 8 49 54 1:CAS:528:DC%2BD1MXhsFKgu7jO 10.1586/erc.09.167 20014934